Novartis AG’s best-selling drug and a key new cancer medicine posted disappointing sales last quarter, even as the Swiss drugmaker lifted profit guidance for a third straight quarter. Sales of heart ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Novartis raised its full-year guidance for the third time this year after higher third-quarter profit and sales topped ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

The MHRA said that Novartis' drug warranted inclusion in the EAMS because "despite different available treatment options, patients with heart failure, especially those with reduced ejection ...

Total net sales at Novartis AG grew by 10% to $12.8bn (€11.9bn ... The highest-selling medicines of the company, included the ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

Schrödinger Inc.’s stock soared 14% Tuesday to put in on track for its biggest one-day gain in a year, after the company said ...

Sales of heart failure medication Entresto fell short of expectations, while closely watched cancer drug Pluvicto only beat estimates because of a one-time gain. The results pushed Novartis shares ...

Novartis has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from approving it, though the generic's launch faces ...

Novartis forecasts full-year sales growth ... and volume growth in core indications. Heart failure drug Entresto sales increased 26% to $1.87 billion, a demand-led growth. The drug has increased ...